Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Receivables - Net (2019 - 2023)

Historic Receivables - Net for Pliant Therapeutics (PLRX) over the last 5 years, with Q2 2023 value amounting to $1.6 million.

  • Pliant Therapeutics' Receivables - Net fell 6833.03% to $1.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.6 million, marking a year-over-year decrease of 6833.03%. This contributed to the annual value of $2.0 million for FY2022, which is 75.08% down from last year.
  • Latest data reveals that Pliant Therapeutics reported Receivables - Net of $1.6 million as of Q2 2023, which was down 6833.03% from $3.3 million recorded in Q1 2023.
  • In the past 5 years, Pliant Therapeutics' Receivables - Net ranged from a high of $9.3 million in Q4 2020 and a low of $1.2 million during Q1 2022
  • Moreover, its 5-year median value for Receivables - Net was $2.1 million (2021), whereas its average is $3.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 7846.75% in 2021, then surged by 17262.3% in 2022.
  • Pliant Therapeutics' Receivables - Net (Quarter) stood at $7.1 million in 2019, then soared by 31.58% to $9.3 million in 2020, then tumbled by 78.47% to $2.0 million in 2021, then dropped by 0.75% to $2.0 million in 2022, then fell by 20.32% to $1.6 million in 2023.
  • Its last three reported values are $1.6 million in Q2 2023, $3.3 million for Q1 2023, and $2.0 million during Q4 2022.